Trial · NCT00423592
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
The Incidence of Confirmed Serum Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Concentrations > 3 x the Upper Limit of Normal (ULN) Considered to be Related to Ambrisentan and Resulted in Discontinuation of Study Drug. | Ambrisentan | 0 | Participants | ||
| The Incidence of Confirmed Serum ALT or AST Concentrations > 5 x ULN That Were Related to Ambrisentan and Resulted in Discontinuation of Study Drug. | Ambrisentan | 0 | participants | ||
| The Incidence of Confirmed Serum ALT or AST Concentrations > 3 x ULN That Were Related to Ambrisentan and Resulted in Dose Reduction | Ambrisentan | 0 | participants | ||
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in the 6-Minute Walk Distance Test (6MWD) | Ambrisentan | 23.4 | Standard Deviation 49.60 | meters | |
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in Borg Dyspnea Index Immediately Following Exercise | Ambrisentan | -0.5 | Standard Deviation 1.51 | Units on a scale | |
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in WHO Functional Class | Ambrisentan | Improved | 15 | Participants | |
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in WHO Functional Class | Ambrisentan | No Change | 18 | Participants | |
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in WHO Functional Class | Ambrisentan | Deteriorated | 2 | Participants | |
| A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in Short Form 36 (SF-36) Health Survey Scale - Composite Physical Health | Ambrisentan | 4.6 | Standard Deviation 6.44 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Composite Mental Health | Ambrisentan | 3.4 | Standard Deviation 8.98 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Physical Functioning | Ambrisentan | 4.4 | Standard Deviation 6.86 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Role Physical | Ambrisentan | 7.2 | Standard Deviation 10.56 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Bodily Pain | Ambrisentan | 3.1 | Standard Deviation 6.40 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - General Health | Ambrisentan | 3.0 | Standard Deviation 7.45 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Vitality | Ambrisentan | 4.5 | Standard Deviation 7.23 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Social Functioning | Ambrisentan | 3.5 | Standard Deviation 9.41 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Role Emotional | Ambrisentan | 3.9 | Standard Deviation 13.96 | Units on a scale | |
| Secondary Outcome: A Change From Baseline Evaluated After 12 Weeks of Ambrisentan Therapy in SF-36 Health Survey Scale - Mental Health | Ambrisentan | 3.9 | Standard Deviation 5.78 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00423592/results